The association between a fracture risk tool and frailty: Geelong Osteoporosis Study

Monica C. Tembo 1*, Kara L. Holloway-Kew 1, Mohammadreza Mohebbi 2, Sophia X. Sui 1, Sarah M. Hosking 1,3, Sharon L. Brennan-Olsen 4,5,6, Lana J. Williams 1, Mark A. Kotowicz 1,5,7 and Julie A. Pasco 1,5,7

Abstract

Background: Frailty is characterised by age-related declines in physical, psychological and social functioning. Features of frailty overlap with risk factors for fragility fractures. The aim of this study was to investigate the association between the fracture risk assessment tool (FRAX®) and frailty.

Methods: In cross-sectional analysis, frailty status was determined for participants aged 60-90 yr at 15-year follow-up of the Geelong Osteoporosis Study, using a modified Fried frailty phenotype. Using the FRAX on-line tool, scores for hip and major osteoporotic fracture (MOF) were calculated with and without bone mineral density (BMD). Using the area under Receiver Operating Characteristic (AUROC) curves, and FRAX scores calculated at the baseline visit for these participants, we investigated the association of FRAX and frailty 15 years later.

Results: Forty-seven of 303 women (15.5%) and 41 of 282 men (14.5%) were frail at the 15-year visit. There was a gradient of increasing median FRAX scores from robust to frail. For example, for women, median MOF-FRAX without BMD increased from 5.9 for the robust to 7.5 for the pre-frail and 14.0 for the frail (p < 0.001). In secondary analyses, an association was observed between FRAX and frailty over 15 years, with the highest AUROC for women being 0.72 for MOF-FRAX with BMD, and for men, 0.76 hip-FRAX without BMD.

Conclusion: An association was observed between FRAX and frailty where frail men and women had higher FRAX-scores compared to the other groups. Preliminary data suggest that FRAX, with or without BMD, may be useful in enhancing the information on frailty. Further research using larger datasets will be required to explore this.

Keywords: Frailty, FRAX, Association, Older adults

Background

Frailty is a clinical syndrome characterised by age-related declines of physical, psychological and social functioning [1, 2]. Frailty increases vulnerability to adverse health outcomes, such as falls, fractures, hospitalisation and disability, associated with diminished ability to compensate for disruptions in homeostasis and minor stressors [3, 4]. Prevalence estimates for frailty vary due to the heterogeneity among the frailty assessment tools currently available. The most commonly used and widely validated tools for assessing frailty are the frailty phenotype and frailty index of deficit accumulation [5].

Frailty is associated with body compositional changes, sarcopenia and osteoporosis, having overlapping pathogenic pathways related to loss of lean muscle mass and function and skeletal deterioration [6]. Osteoporosis is characterised by low bone mineral density (BMD) and deteriorated microarchitecture [7] resulting in increased bone fragility and fracture risk. Emerging studies suggest that frailty may be an effective predictor of osteoporotic fracture [8, 9], since individuals with severe frailty have an increased likelihood of prevalent and incident

* Correspondence: mctembo@deakin.edu.au
1 Epi-Centre for Healthy Ageing, Deakin University, PO Box 281, Geelong, Victoria 3220, Australia
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
fractures [7, 10]. Previous studies have reported that measures of frailty can predict the risk and occurrence of falls and fall-related fractures [3, 8, 9, 11]. There is also an overlap between the characteristics of individuals with frailty and fragility fracture [10].

With the afore mentioned overlap between frailty and fragility fractures, and the existence of numerous frailty tools, some of which are challenging to use in the clinical setting (particularly those with objective measures) [12], investigating the association between fracture risk tools and frailty would be of interest. The fracture risk assessment (FRAX) tool, developed by the University of Sheffield and currently used internationally in the clinical setting, is online and computer-based [13]. It calculates 10-year fracture risk probabilities of hip and major osteoporotic fracture (MOF; inclusive of hip, clinical spine, forearm, proximal humerus) using routinely collected clinical risk factors in adults aged 40–90 years [14, 15]. FRAX was developed using primary data from nine population-based cohorts in multiple countries including centres in North America, Europe, Asia and Australia. Clinical risk factors for fracture that provide independent information on fracture risk were identified using a series of meta-analyses [14]. These clinical risk factors include age, current weight, height, prior low trauma fracture, parental hip fracture, current smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis and alcohol intake. These clinical risk factors are entered into the online tool and the algorithm generates 10-year fracture risk probabilities from the inputted data. Fracture probability may be calculated with or without BMD and, thus, an individual can have up to four probability scores: hip fracture 10-year probability scores with and without BMD, as well as MOF 10-year probability scores with and without BMD [13, 15]. The higher the FRAX score, the higher the fracture risk [15]. The FRAX algorithm has been validated in 11 independent cohorts and models have been calibrated for different countries using country-specific fracture and mortality rates [13, 14]. Currently there are FRAX models available for 31 countries [13].

Most studies have shown that frailty status predicts fracture risk, likely due to frailty and bone fragility having overlapping risk factors. Thus, the primary aim of the study was to investigate the association between the FRAX tool and frailty in cross-sectional analyses. The secondary aim was to explore the association between FRAX calculated at one time point and frailty measured 15 years later.

Methods

Participants
The current study utilised data from the Geelong Osteoporosis Study (GOS), a longitudinal population-based cohort study of randomly selected adults from the Barwon Statistical Division in south-eastern Australia. At baseline, 1494 women and 1540 men were recruited; a comprehensive description of the study has been provided elsewhere [16]. Data from two visits, 15 years apart, were used in this study. For the women, this was baseline (1993–1997) and the follow-up (defined as the 15-year visit) (2011–2014). For the men, this was also baseline (2001–2006) and follow-up (2016–2019). This study included two analyses. A cross-sectional, exploratory analysis was conducted, investigating the association between FRAX-scores and frailty at the 15-year follow-up visits for both women and men. Subsequently, secondary analyses were completed to investigate the association between FRAX-scores calculated at baseline and frailty over a 15-year period. Further details are described below.

Participants underwent assessment using dual energy x-ray absorptiometry (DXA), anthropometry and test of functional mobility in conjunction with questionnaire data concerning health and lifestyle behaviours [16]. The questionnaires and protocols for clinical measurements used to obtain these data were consistent for women and men at all visits.

Cross-sectional analysis
In these analyses, 282 men and 303 women aged 60–90 years at the 15-year follow-up visit were included. The sampling process is shown in Figs. 1a and b.

Secondary analysis
From the baseline visit for the women, 849 women (aged ≥20 years) returned for the follow-up, of whom 302 women (aged 41–75 years) were included in these analyses. The reasons for loss to follow-up included death (n = 392), migration from the region (n = 94), unable to be contacted (n = 128). Another 277 women declined to participate citing following reasons: personal reasons (e.g., n = 108), old age/unable to cope (n = 78), time constraints (n = 36), illness (n = 21), too far to travel (n = 15), failure to keep appointment (n = 4), language barrier (n = 1) and for reasons not provided (n = 8) [17].

For the men, of the 624 men (aged ≥20 years) that returned for the 15-yr visit, 302 (aged 46–82 years) were included in these analyses. From baseline, 242 were lost to follow-up at the 15-year visit for the following reasons: personal reasons (n = 108), old age/unable to cope (n = 48), time constraints (n = 45), illness (n = 33), too far to travel (n = 2), failure to keep appointment (n = 4), language barrier (n = 1) and for reasons not provided (n = 8). Reasons for non-participation also included death (n = 425), migration from region (n = 24), unable to consent (n = 9) and unable to be contacted (n = 216) (Fig. 1a&b).
Ethical considerations
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Barwon Health Human Research Ethics Committee.

Written, informed consent was obtained from all participants in the study.

Frailty assessment
At the 15-year follow-up, frailty was identified using a modified Fried frailty phenotype, which categorised participants into frail, pre-frail or robust groups [2]. This tool used five items; unintentional weight loss, exhaustion, low physical activity, weakness and slowness. Unintentional weight loss, exhaustion and low physical activity were ascertained by self-reported questionnaires. Weakness was determined using handgrip strength (HGS), measured using a hand-held Jamar device (Sammons Preston, Bolingbrook, IL, UK) for women and Venier (Venier Software and Technology, Beaverton, USA) for men. To align our measurements as close as possible to the Fried criteria, HGS values for the men were transformed to Jamar equivalent values. This was done because the Fried criteria for frailty utilises cut-off points for muscle weakness from the Jamar device. The equation that was used was: \( \text{MeanHGS}_{\text{Jamar}} (\text{kg}) = 8.68 + 0.840 \times \text{MeanHGS}_{\text{Venier}} (\text{kg}) + 8.31 \times \text{Sex} \) (where male = 1).

The conversion equation was developed by measuring the maximum HGS on each device for 45 men and women aged 21–67 years. Weakness was defined by cut-points from the Fried phenotype derived from the lowest 20% stratified by sex and body mass index [2]. Slowness was measured using timed up and go (TUG) test. A score of greater than 10 s is considered as being slow [18]. Having three or more of these items categorised a person as frail, 1–2 as pre-frail, and none as robust.

For the secondary analyses, we sought to exclude participants who may have had any indication of frailty at baseline. As there were insufficient data to calculate the Fried phenotype at baseline, we used a modified Frailty Index of deficit accumulation that was constructed using guidelines from Searle et al. [16] but included only 18 health variables (Additional file 1 Table A.1). Those who had indications for frailty at baseline (n = 2 men only) were excluded from these analyses. Self-reported data were used in the construction of the index, with the exception of BMI (height and weight were measured, then BMI calculated) and high blood pressure, which was measured using a digital sphygmomanometer. High blood pressure referred to systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.

Fracture risk assessment
FRAX (Australia) [15] was calculated using the following information; age, current weight, height, participants self-reported parental hip fractures, current smoking status, glucocorticoid use, rheumatoid arthritis. Secondary
osteoporosis comprised type I (insulin dependent) diabetes, osteogenesis imperfecta in adults, untreated longstanding hyperthyroidism, hypogonadism or premature menopause (<45 years), chronic malnutrition, or malabsorption and chronic liver disease. This information was captured by questionnaire, except for malnutrition where BMI < 18.5 kg/m² was used as a proxy. Previous low trauma fractures were identified from radiological reports [16]. BMD at the femoral neck was measured using dual energy x-ray absorptiometry (DXA; Lunar Prodigy-Pro, Madison, WI, USA). Alcohol consumption was derived from the Victorian Cancer Council Food Frequency Questionnaire [19] and converted into a binary value (cut-point was alcohol consumption of ≥30 g/day) for use in FRAX for all data except men 15-year follow-up, where it was identified by questionnaire [16]. Ten-year FRAX probabilities for MOFs and hip fracture with and without BMD were calculated using the online tool for each participant. Each participant had four scores generated, MOF FRAX scores without BMD (MOF-FRAXnoBMD), hip FRAX score without BMD (hip-FRAXnoBMD), MOF FRAX scores with BMD (MOF-FRAXBMD), and hip FRAX with BMD (hip-FRAXBMD).

Only participants with complete data at either visit were included.

### Statistical analyses

#### Cross-sectional data analysis

Cross-sectional data analysis for examining differences in FRAX scores between the three frailty groups at the 15-year follow-up was completed using Kruskal-Wallis test for non-parametric data. The secondary analyses investigated the association of FRAX at baseline and frailty at the 15-year follow-up. Area under Receiver operating characteristic (AUROC) curves and diagnostic characteristics tests including sensitivity, specificity and likelihood ratios were performed. This was done by examining the sensitivity and specificity for decile cut-points and selecting the cut-point with an optimal combination of sensitivity and specificity. Minitab (Version 18, State College, PA, USA) and STATA (Version 16, College Station, Texas, USA) statistical software were used for statistical analyses.

## Results

### Cross-sectional analysis

Descriptive characteristics are summarised in Table 1.

| Women | All | Frail | Pre-frail | Robust | P-value |
|-------|-----|-------|-----------|--------|---------|
| N = 303 | N = 47 | N = 168 | N = 88 |
| Age (yr) | 70 (65–75) | 76 (70–84) | 70 (65–75) | 67 (63–72) | <0.001 |
| Weight (kg) | 73.7 ± 15.0 | 73.0 ± 15.0 | 74.7 ± 15.0 | 72.4 ± 15.0 | 0.474 |
| Height (m) | 1.60 ± 0.06 | 1.57 ± 0.06 | 1.60 ± 0.06 | 1.61 ± 0.06 | 0.004 |
| Body mass index (kg/m²) | 29.0 ± 5.7 | 29.4 ± 5.5 | 29.4 ± 5.9 | 28.0 ± 5.3 | 0.141 |
| Femoral neck bone mineral density (g/cm²) | 0.835 ± 0.130 | 0.801 ± 0.136 | 0.844 ± 0.136 | 0.835 ± 0.108 | 0.127 |

### Men

| N = 282 | N = 41 | N = 147 | N = 94 |
|---------|-------|--------|-------|
| Age (yr) | 71 (66–78) | 78 (73–74) | 71 (66–79) | 68 (64–71) | <0.001 |
| Weight (kg) | 82.7 ± 12.4 | 88.1 ± 13.2 | 82.0 ± 12.7 | 81.4 ± 11.09 | 0.011 |
| Height (m) | 1.72 ± 0.08 | 1.71 ± 0.08 | 1.72 ± 0.06 | 1.73 ± 0.10 | 0.510 |
| Body mass index (kg/m²) | 28.0 ± 4.3 | 30.1 ± 4.1 | 27.5 ± 3.6 | 27.5 ± 5.1 | 0.002 |
| Femoral neck Bone mineral density (g/cm²) | 0.935 ± 0.137 | 0.961 ± 0.153 | 0.921 ± 0.123 | 0.947 ± 0.149 | 0.158 |

#### FRAX scores

| Women | MOF-FRAXBMD | MOF-FRAXnoBMD | Hip-FRAXBMD | Hip-FRAXnoBMD |
|-------|-------------|---------------|-------------|---------------|
| N = 303 | 12.0 (5.7–17) | 14.0 (6.5–28) | 3.8 (1.3–6.1) | 5.8 (2.0–13) |

| Men | MOF-FRAXBMD | MOF-FRAXnoBMD | Hip-FRAXBMD | Hip-FRAXnoBMD |
|-----|-------------|---------------|-------------|---------------|
| N = 282 | 4.2 (3.0–5.5) | 6.2 (4.0–7.3) | 1.6 (0.8–2.3) | 3.1 (1.6–3.8) |

*aFracture risk assessment (FRAX), Major Osteoporotic Fractures (MOF) FRAX score with Bone mineral density (BMD)(MOF-FRAXBMD), MOF FRAX score without BMD (MOF-FRAXnoBMD), hip FRAX with BMD (hip-FRAXBMD), hip FRAX score without BMD (hip-FRAXnoBMD)
Women
Of 303 women, 47 (15.5%) were frail, 168 (55.4%) pre-frail and 88 (29.0%) robust at the 15-year follow-up. There were differences in age and height between the frailty groups, where median age increased across the frailty groups and the mean height decreased across the frailty groups. No differences in weight, BMI and BMD were detected between the three groups. The frail group had higher median scores for all four FRAX scores compared to the pre-frail and robust groups (Table 1).

Men
Of 282 men, 41 (14.5%) were frail, 147 (52.1%) pre-frail and 94 (33.3%) robust at the 15-year follow-up. Frail men were older in age, weighed more and had a higher BMI compared to the pre-frail and robust groups; otherwise the groups were similar. Analysis revealed that the frail group had higher median scores for all four FRAX scores compared to the pre-frail and robust groups (Table 1).

Secondary analyses
Women
In a non-response analysis, individuals at baseline who did not participate at the 15-year follow-up were found to be older, shorter and weigh less compared to those who participated (data not shown). At baseline, only one woman was identified with 25% deficits on the 18 health variables but none had greater than 25% of total deficits. Thus, no participants had indications of frailty at baseline (Additional file 1 Table A.1). FRAX risk factors for women at baseline, according to frailty status at 15-year follow-up, are summarised in Table 2. Prior fracture and glucocorticoid use were associated with frailty, with the frail group having higher proportions compared to the other two groups. There was also a correlation between frailty and age, height and BMD, where women in the frail group were older, shorter and had a lower BMD. The median time of follow-up between baseline and 15-year follow-up was 16.5 years (IQR 15.78–16.96). FRAX scores increased over time (data not shown).

Table 2 FRAX variables for men and women at baseline and according to frailty status at 15-year follow-up. Values reported as means ±SD, median (IQR), or n (%)

| Variable                          | ALL  | Frail | Pre-frail | Robust | P-value |
|-----------------------------------|------|-------|-----------|--------|---------|
| **Women**                         | N = 302 | N = 46 | N = 168 | N = 88 |         |
| Age (yr)                          | 53 (48–73) | 62 (53–67) | 53 (47–60) | 51 (47–56) | ≤ 0.001 |
| Weight (kg)                       | 70.8 ± 13.1 | 71.7 ± 13.3 | 71.2 ± 13.2 | 69.6 ± 12.9 | 0.583 |
| Height (cm)                       | 161.3 ± 6.0 | 159.3 ± 5.2 | 161.3 ± 6.0 | 162.4 ± 6.1 | 0.018 |
| Prior Fracture                    | 31 (10.3) | 11 (24.0) | 13 (7.7) | 7 (8.0) | 0.004 |
| Parental hip fracture             | 18 (6.0) | 4 (8.7) | 10 (6.0) | 4 (4.5) | 0.629 |
| Smoking                           | 33 (10.9) | 3 (6.5) | 22 (13.1) | 8 (9.1) | 0.362 |
| Glucocorticoids                   | 2 (0.6) | 1 (2.2) | 1 (0.6) | 0 (0) | 0.145 |
| Rheumatoid Arthritis              | 24 (7.9) | 8 (17.4) | 14 (8.3) | 2 (2.3) | 0.009 |
| Secondary Osteoporosis            | 36 (11.9) | 4 (8.7) | 25 (14.9) | 7 (8.0) | 0.204 |
| Alcohol                           | 2 (0.7) | 0 (0) | 0 (0) | 2 (2.3) | 0.657 |
| BMD (g/cm²)                       | 0.928 ± 0.146 | 0.876 ± 0.150 | 0.933 ± 0.153 | 0.946 ± 0.124 | 0.025 |

| Variable                          | Men  | N = 302 | N = 46 | N = 158 | N = 98 | P-value |
|-----------------------------------|------|---------|--------|---------|--------|---------|
| Age (years)                       | 57 (52–65) | 68 (60–76) | 57 (66–52) | 54 (51–59) | ≤ 0.001 |
| Weight (kg)                       | 83.7 ± 12.7 | 87.3 ± 12.9 | 83.0 ± 13.0 | 83.3 ± 11.9 | 0.108 |
| Height (cm)                       | 174.5 ± 6.4 | 173.7 ± 7.2 | 174.4 ± 6.1 | 175.0 ± 6.4 | 0.496 |
| Prior Fracture                    | 49 (16.2) | 6 (13.0) | 29 (18.4) | 14 (14.3) | 0.565 |
| Parental hip fracture             | 23 (7.6) | 3 (6.5) | 15 (9.5) | 5 (5.1) | 0.417 |
| Smoking                           | 31 (10.3) | 3 (6.5) | 17 (5.6) | 11 (11.2) | 0.657 |
| Glucocorticoids                   | 1 (0.3) | 0 (0) | 1 (0.6) | 0 (0) | 0.145 |
| Rheumatoid Arthritis              | 7 (2.3) | 1 (2.2) | 6 (3.8) | 0 (0) | 0.145 |
| Secondary Osteoporosis            | 4 (1.3) | 0 (0) | 4 (14.9) | 0 (0) | 0.095 |
| Alcohol                           | 82 (27.2) | 12 (26.1) | 44 (27.8) | 26 (26.5) | 0.009 |
| BMD (g/cm²)                       | 0.982 ± 0.127 | 1.016 ± 0.150 | 0.962 ± 0.116 | 1.000 ± 0.127 | 0.009 |

*Too few to conduct statistical analysis

**Bone mineral density (BMD)**
In discriminating frailty groups, the AUROC analysis of FRAX scores demonstrated the greatest value for MOF-FRAX\textsubscript{BMD} (0.72). Slightly lower values were observed for MOF-FRAX\textsubscript{noBMD} (0.71). The FRAX scores for the hip displayed a similar pattern; hip-FRAX\textsubscript{BMD} demonstrated a slightly increased AUROC curve compared to hip-FRAX\textsubscript{noBMD} (0.69 and 0.68). The lowest AUROC values were observed for BMD alone (0.62). When comparing the association between FRAX tool and BMD alone with frailty, the association between FRAX tool was better as indicated by the AUROC curve (0.72 versus 0.62 respectively) (Table 3). Using AUROC analysis to determine preliminary cut-points for optimum sensitivity and specificity in determining frailty, the fifth decile was the optimal point for all FRAX scores, with MOF-FRAX\textsubscript{BMD} having the optimal values based on AUROC curve (AUROC = 0.72, sensitivity = 80.0%, specificity = 45.7%) (Table 3).

**Men**

Similar to the women, in the non-response analysis, participants that did not attend the 15-year follow-up visit were older, shorter and weighed less (data not shown). Among the men screened at baseline, only two showed indications of frailty with > 25% deficits of the 18 health variables (Additional file 1 Table A.1), and were excluded from the longitudinal data analyses. FRAX risk factors for men at baseline, according to frailty status at 15-year follow-up are summarised in Table 2. Age and BMD were correlated with frailty. The median time of follow-up between baseline and 15-year follow-up was 13.9 years (IQR 13.4–14.5). FRAX scores increased over time (data not shown).

The ROC analyses demonstrated that the area under the ROC curve was greater for FRAX scores than for BMD alone (Table 3). In descending order, hip-FRAX\textsubscript{noBMD} had the greatest AUROC value (0.76), followed by MOF-FRAX\textsubscript{noBMD} (0.73), then MOF-FRAX\textsubscript{BMD} (0.68), then hip-FRAX\textsubscript{BMD} (0.67) and BMD alone (0.57). Using the AUROC analysis to determine preliminary cut-points for optimum sensitivity and specificity in determining an association with frailty, the fifth decile was the optimal point for all FRAX scores, with hip-FRAX\textsubscript{noBMD} having the optimal values based on AUROC curve (sensitivity = 89.6%, specificity = 45.7%) (Table 3).

### Discussion

This study demonstrates that men and women with frailty had the highest FRAX scores compared to the pre-frail and robust groups, indicating that FRAX is associated with frailty. Compared to using BMD alone, the FRAX tool showed a better association. For women, the difference in AUROC curves between MOF-FRAX

### Table 3 Determination of Fracture Risk Assessment (FRAX) score cut-off points for screening for frailty using Area under the Receiver Operating Characteristic (AUROC) curves using sensitivity and specificity measures

| FRAX scores | Area under the ROC curve (95% CI) | Cut point (Decile) | % Cut point for fracture risk | Sensitivity | Specificity | Predictive Value (%) | Positive Likelihood ratio (LR+) | Negative Likelihood ratio (LR-) |
|-------------|----------------------------------|-------------------|-----------------------------|------------|------------|----------------------|-------------------------------|-------------------------------|
| **Women**   |                                  |                   |                             |            |            |                      |                               |                               |
| MOF\textsuperscript{5} with BMD\textsuperscript{c} | 0.72 (0.63–0.80)     | 5                 | 1.50 (1.06,1.94)           | 80.0%      | 45.7%      | 50.8                 | 1.47                          | 0.44                          |
| MOF without BMD | 0.71 (0.62–0.79)     | 5                 | 1.60 (1.21,1.99)           | 82.2%      | 45.0%      | 50.5                 | 1.50                          | 0.40                          |
| Hip with BMD | 0.69 (0.60–0.78)       | 5                 | 0.10 (0.00,0.38)           | 84.4%      | 30.2%      | 38.3                 | 1.21                          | 0.51                          |
| Hip without BMD | 0.68 (0.60–0.77)      | 5                 | 0.20 (0.02,0.38)           | 75.6%      | 49.2%      | 53.1                 | 1.49                          | 0.50                          |
| **Men**     |                                  |                   |                             |            |            |                      |                               |                               |
| Hip without BMD | 0.76 (0.68–0.82)     | 5                 | 0.30 (0.12,1.94)           | 89.6%      | 45.7%      | 52.6                 | 1.64                          | 0.23                          |
| MOF without BMD | 0.73 (0.66–0.80)     | 5                 | 1.65 (1.36,1.94)           | 87.5%      | 47.7%      | 54.0                 | 1.67                          | 0.26                          |
| MOF with BMD | 0.68 (0.60–0.76)       | 5                 | 1.70 (1.45,1.95)           | 79.2%      | 46.5%      | 51.6                 | 1.48                          | 0.45                          |
| Hip with BMD | 0.67 (0.59–0.75)       | 5                 | 0.20 (0.05,0.35)           | 81.3%      | 44.1%      | 50.0                 | 1.45                          | 0.42                          |

\*Reported as median (95% CI) fracture risk percentage

\textsuperscript{5} MOF Major Osteoporotic fractures

\textsuperscript{c} BMD Bone mineral density
scores with and without BMD was small. For men, FRAX scores without BMD were better overall, with hip-FRAX having a slightly higher area under the curve compared to MOF-FRAX score.

This study showed that frail women tended to have lower femoral neck BMD. These results are similar to previous studies that demonstrated that frail individuals had lower femoral neck BMD [20, 21]. In a study of community-dwelling older women, those who were frail at baseline using the Vulnerable Elders Survey (VES-13) had lower spine and hip BMD at 1 year follow up [22] whereas frail men tended to have higher BMD. These results are similar to those of Cook et al. [23] who reported femoral neck BMD was not lower in frail men; however, it should be noted that these data were derived using the Rockwood frailty index and not the Fried frailty phenotype. Our data suggest that FRAX scores are better associated with frailty compared to BMD alone. BMD was shown to be minimally associated with frailty. This may be explained by the FRAX tool’s inclusion of risk factors that are also associated with frailty [24]. These risk factors include age, weight and height, fractures, diabetes, malnutrition, smoking and alcohol [2, 25–29]. We hypothesise that malnutrition could lead to muscle loss, which could result in muscle weakness and fatigue as specifically outlined in the definition of frailty by Fried et al. [2].

In the secondary analyses, we identified most participants who went on to become frail (sensitivity 80%). However, our results also indicated a high number of false positives. Thus, the association between FRAX and frailty could be beneficial in enhancing the knowledge currently available for frailty.

Results of the current study revealed an association between FRAX and frailty. This information can enhance our understanding of frailty and open an exploratory avenue for research focusing on the utility of this tool. If this utility is possible, it would be advantageous, as it will utilise information that is readily available and allow screening and possible identification of those that are at risk of being frail, who can then be investigated further using validated tools. This might also permit targeting of interventions for delay or prevention of frailty development. While this tool is unidimensional in its functionality, addressing only the physical components of frailty, it has the advantage of being an online calculation tool, using readily available information [13].

Our study has a number of strengths including the random selection of participants from the general population, and the use of many objective measures in calculations of frailty scores. However, it should be noted that our sample is a nested cohort from a bigger study. Limitations of this research include the use of some self-reported information, loss to follow-up between the two time points and the use of a modified Fried phenotype to identify frailty. However, the prevalence of frailty using the modified Fried phenotype tool mirrors that of previous studies undertaken in populations with similar characteristics [2, 30, 31]. Data were collected at different time points for the men and women (5 years apart), by different research personnel; however, all personnel were trained and the same questionnaires and protocols for measurements were utilised at each visit. The age range for our study participants was limited to older adults, specifically between the ages of 40–90 years (due to FRAX age limitation); however, it should be noted that most studies on frailty use participants aged 60 years and older as this is the age range at higher risk of frailty [2, 12, 32]. We acknowledge that the older old participants (≥80 yr) are more likely to have more characteristics for frailty [33]. Between the two time points used, there was attrition due to death, relocation, non-respondents and withdrawal from the study. Our participants were generally healthy as they were from the general population. As such, we did not expect to have many frail individuals. If recruitment had been from an aged-care setting, then a larger number of frail individuals would likely have been identified. We recognise the potential for differential loss to follow-up on the basis of disability and the likelihood of a healthy survivor effect. While only two men had indications of frailty at baseline, we acknowledge the limitation of using the modified frailty index of deficit accumulation, as it only had 18 items rather than the recommended minimum of 30. The frailty index of deficit accumulation was used only to identify people for whom there was an indication of frailty because insufficient data were available at baseline to determine the Fried phenotype for the purposes of exclusion. However, within these constraints, an association was observed and we suggest further research into the utility of FRAX in the evaluation of frailty in larger cohorts. Finally, the current study investigated FRAX and frailty in a population-based sample of adults who are predominantly Caucasian (98%) and so further research is necessary to determine whether FRAX is associated with frailty in other culturally diverse populations.

Conclusion
The results of this study show an association between FRAX and frailty cross-sectionally and over 15 years. Preliminary results suggest that FRAX could enhance the knowledge surrounding frailty. Further research using larger and more culturally diverse datasets will be required to determine the utility of this tool.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12877-020-01595-8.
Abbreviations
BMD: Bone mineral density; FRAX: Fracture risk assessment; MOF: Major osteoporotic fracture; GOS: Geelong Osteoporosis Study; DXA: Dual energy x-ray absorptiometry; HGS: Hand grip strength; TUG: Timed up and go; BMI: Body mass index; MOF-FRAX<sub>noBMD</sub>: Major osteoporotic fracture risk assessment scores without bone mineral density; MOF-FRAX<sub>BMD</sub>: Major osteoporotic fracture risk assessment scores with bone mineral density; hip-FRAX<sub>noBMD</sub>: Hip fracture risk assessment scores without bone mineral density; hip-FRAX<sub>BMD</sub>: Hip fracture risk assessment scores with bone mineral density; AUROC: Area under Receiver operating characteristic; IQR: Interquartile range; SD: Standard deviation

Acknowledgements
The authors acknowledge the men and women who participated in the study. The authors thank Professor Graham Giles of the Cancer Epidemiology Centre of The Cancer Council Victoria, for permission to use the Dietary Questionnaire for Epidemiological Studies (Version 2), Melbourne: The Cancer Council Victoria, 1996.

Authors’ contributions
MCT: Conceptualization, design, acquisition, data analysis, writing-Original Draft, Writing-Review and Editing. KLH-K: Data analysis, Writing-Review and Editing. MM: Data analysis, Writing-Review and Editing. SXS: Writing-Review and Editing. SMH: Writing-Review and Editing SB-O: Writing-Review and Editing. LJW: Writing-Review and Editing. MAK: Writing-Review and Editing JAP: Conceptualization, Methodology, Formal Analysis, Writing-Review and Editing. All Authors have approved the submitted version and are accountable for all parts of the study and all other aspects of the study.

Funding
The Geelong Osteoporosis Study (GOS) was funded by the National Health and Medical Research Council (NHMRC) Australia (projects 299831, 251638, 628582). The funding organisation played no role in the design or conduct of the study, in the collection, management, analysis and interpretation of the data, nor in the preparation, review and approval of the manuscript. MCT and SXS were supported by Deakin Postgraduate Scholarships, KLH-K was supported by Alfred Deakin Postdoctoral Research Fellowship, LJW is supported by NHMRC Career Development Fellowship (1064272) and a NHMRC Investigator grant (1174060), SB-O was supported by NHMRC Career Development Fellowship (1107510) and SMH by a Faculty of Health Research Fellowship from Deakin University.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Barwon Health Research Ethics Committee. Written, informed consent was obtained from all participants in the study.

Consent for publication
Not Applicable.

Competing interests
The authors have declared that no competing interests exist.

Author details
1Epi-Centre for Healthy Ageing, Deakin University, PO Box 281, Geelong, Victoria 3220, Australia. 2Faculty of Health, Biostatistics Unit, Deakin University, Geelong, VIC, Australia. 3Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. 4Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne, St Albans, Australia. 5School of Health and Social Development, Deakin University, Geelong, VIC, Australia. 6Barwon Health, Geelong, Australia.

Received: 18 December 2019 Accepted: 27 May 2020

References
1. Drey M, Pfeifer K, Sieber CC, Bauer JM. The fried frailty criteria as inclusion criteria for a randomized controlled trial: personal experience and literature review. Gerontology. 2010.
2. Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol. 2001;56(3):M146–56.
3. Liu UK, Lee WL, Chen LY, Hwang AC, Lin MH, Peng LN, et al Association between frailty, osteoporosis, falls and hip fractures among community-dwelling people aged 50 years and older in Taiwan: Results from I-Lan Longitudinal Aging Study. PLoS One. 2015;10(9).
4. Iqbal J, Dervit M, Gunn J, Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–62.
5. Sutton JL, Gould RL, Daley S, Coulson MC, Ward EV, Butler AM, et al. Psychometric properties of multicomponent tools designed to assess frailty in older adults: a systematic review. BMC Geriatr. 2016;16(1):55.
6. Cesari M, Landi F, Vellas B, Rabadi R, Mazetti E. Sarcopenia and physical frailty: Two sides of the same coin. Front Aging Neurosci. 2014;6(U1):1–4.
7. Li G, Thabane L, Papaioannou A, Ioannidis G, Levine MAH, Adachi JD. An overview of osteoporosis and frailty in the elderly.
8. Li G, Papaioannou A, Thabane L, Cheng J, Adachi JD. Frailty change and major osteoporotic fracture in the elderly: data from the global longitudinal study of osteoporosis in women 3-year Hamilton cohort. J Bone Miner Res. 2016;31(4):718–24.
9. Tom SE, Adachi JD, Anderson FA, Bonnen S, Chapurlat RD, Compton JE, et al. Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc. 2013;61(3):327–34.
10. van den Bergh JP, van Geel T, A. Reusser PP, osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol. 2012;8(3):163–72.
11. Kennedy CC, Ioannidis G, Rockwood K, Thabane L, Adachi JD, Kirkland S, et al. A frailty index predicts 10-year fracture risk in adults age 25 years and older: results from the Canadian multicentre osteoporosis study (CaMos) Pubmed Central CANADA. Osteoporos Int. 2014;25(2):12:2852–32.
12. Dent E, Koopal P, Hoogendijk EO. Frailty measurement in research and clinical practice: A review. Eur J Internal Med. 2016;13:1–10.
13. Kanis JA, Hans D, Cooper C, Bairn S, Bleakley J, Blinley N, et al. Interpretation and use of FRAX in clinical practice. Osteopores Int. 2011; 229):2395–411.
14. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18(3):1033–46.
15. Kanis JA, Oden A, Johansson H, Borgeström F, Ström O, McCloskey E. FRAX® and its applications to clinical practice. Bone. 2009;44(5):734–45.
16. Pasco JA, Nicholson GC, Kotowicz MA. Cohort profile: Geelong Osteoporosis Study. Int J Epidemiol. 2012;41(6):1565–75.
17. Quirk SE, Berk M, Pasco JA, Bennan-Olsen SL, Chenan AM, Kolwama-Horakken H, et al. The prevalence, age distribution and commodity of personality disorders in Australian women. Aust N Z J Psychiatr. 2017;51(2):141–50.
18. Podsiadlo D, Richardson S. The timed “up & go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.
19. Giles G. Dietary Questionnaire for epidemiological studies (version 2). Cancer Council Victoria. 1996.
20. Kenny AM, Waynik IY, Smith JA, Fortinsky R, Neppinger A, McGee D. Association between level of frailty and bone mineral density in community-dwelling men. J Clin Densitom. 2006;9(3):309–14.
21. Ma SL, Oyler J, Glavin S, Alavi A, Vokes T. Self-reported frailty is associated with low calcaneal bone mineral density in a multicultural population of community-dwelling elderly. Osteoporos Int. 2009;20(11):1837–46.
22. Stenberg SA, Levin R, Dalkadder S, Edelman S, Resnick T, Menczel J. Frailty and osteoporosis in older women – a prospective study. Osteoporos Int. 2014;25(2):763–8.
23. Cock MJ, Olforday A, Pye SR, Ward KA, Gielen E, Ravindranethal R, et al. Frailty and bone health in European men. Age Ageing. 2017;46:635–41.
24. Bolland MJ, Shi AT, Mason BH, Horne AM, Ames WR, Grey AB, et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res. 2011;26(2):420–7.
25. O’Connell ML, Coppinger T, McCarthy AL. The role of nutrition and physical activity in frailty: a review. Clin Nutr ESPEN. 2020;35:1–11.
26. Rolland Y, Abellan van Kan G, Benetos a, Blain H, Bonnefoy M, Chassagne P, et al. Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives. J Nutr Health Aging. 2008;12(5):335–46.
27. Sinclair AJ, Rodriguez-Mañas L. Diabetes and frailty: two converging conditions? Can J Diabetes. 2016;40(1):77–83.
28. Kojima G, Iliffe S, Walters K. Smoking as a predictor of frailty: a systematic review. BMC Geriatr. 2015;15:131.
29. Seematter-Bagnoud L, Spagnoli J, Santos-Eggimman B. Alcohol use and frailty in community-dwelling older persons aged 65 to 70 years. J Frailty Aging. 2014;3(1):9–14.
30. Hoogendijk EO, Deeg DHJ, Poppeliers J, van der Horst M, Broese van Groenou MI, Comijs HC, et al. the longitudinal aging study Amsterdam: cohort update 2016 and major findings. Eur J Epidemiol. 2016;31(9):927–45.
31. Romero-Ortuno R, Walsh CD, Lawlor BA, Kenny RA. A frailty instrument for primary care: findings from the survey of health, ageing and retirement in Europe (SHARE). BMC Geriatr. 2010;10:57.
32. Thompson MG, Theou O, Karnon J, Adams RJ, Visvanathan R. Frailty prevalence in Australia: findings from four pooled Australian cohort studies. Australas J Ageing. 2018;37(2):155–8.
33. Herr M, Jeune B, Fors S, Andersen-Ranberg K, Anki J, Arai Y, et al. Frailty and associated factors among centenarians in the 5-COOP countries. Gerontology. 2018;64(6):521–31.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author/s: 
Tembo, MC; Holloway-Kew, KL; Mohebbi, M; Sui, SX; Hosking, SM; Brennan-Olsen, SL; Williams, LJ; Kotowicz, MA; Pasco, JA

Title: 
The association between a fracture risk tool and frailty: Geelong Osteoporosis Study

Date: 
2020-06-05

Citation: 
Tembo, M. C., Holloway-Kew, K. L., Mohebbi, M., Sui, S. X., Hosking, S. M., Brennan-Olsen, S. L., Williams, L. J., Kotowicz, M. A. & Pasco, J. A. (2020). The association between a fracture risk tool and frailty: Geelong Osteoporosis Study. BMC GERIATRICS, 20 (1), https://doi.org/10.1186/s12877-020-01595-8.

Persistent Link: 
http://hdl.handle.net/11343/244766

File Description: 
published version

License: 
CC BY